Innate Pharma (IPHYF) Stock Price, News & Analysis

Company Overview

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing. Additional preclinical and clinical candidates aim to engage macrophages and other innate immune effectors. Innate Pharma pursues both monotherapy and combination strategies, advancing collaborations with global partners to evaluate its molecules alongside established cancer treatments.

Innate Pharma serves a global patient community through strategic partnerships and research alliances. The company has established joint development agreements with major pharmaceutical firms to accelerate clinical trials and broaden the geographic reach of its investigational therapies. In addition to its Marseille headquarters, Innate Pharma maintains a presence in the United States to support North American clinical and regulatory activities.

Under the leadership of Chief Executive Officer Mondher Mahjoubi and a management team with deep experience in immunology and drug development, Innate Pharma continues to expand its research capabilities and manufacturing infrastructure. With a history of pioneering work in the innate immune checkpoint field, the company seeks to deliver first-in-class or best-in-class immunotherapies that address unmet needs in cancer and beyond.

Key Stats

• Today's Range: $2.00 to $2.00
• 50-Day Range: $1.31 to $2.06
• 52-Week Range: $1.31 to $2.06
• Volume: N/A
• Average Volume: 7,160 shs
• Market Capitalization: $167.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Innate Pharma Stock Analysis - MarketRank™

Innate Pharma scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Innate Pharma.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Innate Pharma has a P/B Ratio of 18.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Innate Pharma does not currently pay a dividend.

Dividend Growth

Innate Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Innate Pharma has been sold short.

Short Interest Ratio / Days to Cover

Innate Pharma has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.23

News Sentiment

Innate Pharma has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Innate Pharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Innate Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.89% of the stock of Innate Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

IPHYF Stock Analysis - Frequently Asked Questions

How have IPHYF shares performed this year?

Innate Pharma's stock was trading at $2.90 at the beginning of the year. Since then, IPHYF stock has decreased by 31.0% and is now trading at $2.00.

How do I buy shares of Innate Pharma?

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IPHYF
• Previous Symbol: NASDAQ:IPHYF
• CIK: 1598599
• Web: www.innate-pharma.com
• Phone: (343) 030-3030
• Fax: 33-04-30-30-30-00
• Employees: 179
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.21
• Quick Ratio: 2.60

Sales & Book Value

• Annual Sales: $21.77 million
• Price / Sales: 7.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.11 per share
• Price / Book: 18.18

Miscellaneous

• Outstanding Shares: 83,830,000
• Free Float: 57,097,000
• Market Cap: $167.66 million
• Optionable: Not Optionable
• Beta: 0.50